Alivus Life Sciences has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a revenue from operations of ₹6,404.14 million. Total income for the quarter stood at ₹6,628.15 million, with a net profit after tax amounting to ₹1,600.76 million. The board also approved the financial results and a limited review report by the auditor.
Alivus Life Sciences Announces Q1 FY27 Financials
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has officially released its unaudited financial results for the first quarter of the financial year 2026-27, ending on June 30, 2026. The company’s Board of Directors approved these results on July 30, 2026.
Key Financial Highlights
For the quarter ended June 30, 2026, Alivus Life Sciences reported the following key figures:
- Revenue from operations: ₹6,404.14 million
- Other income: ₹224.01 million
- Total income: ₹6,628.15 million
- Total expenses: ₹4,505.92 million
- Profit before tax: ₹2,122.23 million
- Tax expenses: ₹521.47 million
- Net profit for the period: ₹1,600.76 million
Comparisons and Other Details
The results also provide comparative figures for the quarter ended March 31, 2026, and the year ended March 31, 2026 (Audited). Basic earnings per equity share for the quarter were ₹13.04. The company has identified Active Pharmaceutical Ingredient (API) as its sole reporting segment.
These financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and have undergone a limited review by the statutory auditors, who have expressed an unmodified conclusion.
Source: BSE
